BACKGROUND: Activating mutations of the thyroid stimulating hormone receptor gene (TSHR) are rare in the neonate and in the pediatric population. They are usually present in the germline, and are either inherited or occur de novo. Somatic mutations in TSHR are unusual in the pediatric population. METHODS: We describe a nine-month-old infant with thyrotoxicosis who harbored an activating somatic mutation in TSHR that was not present in the germline. RESULTS: As genomic DNA analysis failed to show a TSHR gene mutation, a radioiodide scan was performed to reveal a unilateral localization of uptake suppressing the remaining thyroid tissue. Genomic and complementary DNA analyses of the active thyroid tissue, removed surgically, identified a missense mutation (D633Y) located in the sixth transmembrane domain of the TSHR. The absence of this TSHR mutation in circulating mononuclear cells and in unaffected thyroid tissue confirmed the somatic nature of this genetic alteration. CONCLUSIONS: To the authors' knowledge, this is the youngest patient to receive definitive treatment for hyperthyroidism due to an activating mutation of TSHR.
BACKGROUND: Activating mutations of the thyroid stimulating hormone receptor gene (TSHR) are rare in the neonate and in the pediatric population. They are usually present in the germline, and are either inherited or occur de novo. Somatic mutations in TSHR are unusual in the pediatric population. METHODS: We describe a nine-month-old infant with thyrotoxicosis who harbored an activating somatic mutation in TSHR that was not present in the germline. RESULTS: As genomic DNA analysis failed to show a TSHR gene mutation, a radioiodide scan was performed to reveal a unilateral localization of uptake suppressing the remaining thyroid tissue. Genomic and complementary DNA analyses of the active thyroid tissue, removed surgically, identified a missense mutation (D633Y) located in the sixth transmembrane domain of the TSHR. The absence of this TSHR mutation in circulating mononuclear cells and in unaffected thyroid tissue confirmed the somatic nature of this genetic alteration. CONCLUSIONS: To the authors' knowledge, this is the youngest patient to receive definitive treatment for hyperthyroidism due to an activating mutation of TSHR.
Authors: M Tonacchera; L Chiovato; A Pinchera; P Agretti; E Fiore; F Cetani; R Rocchi; P Viacava; P Miccoli; P Vitti Journal: J Clin Endocrinol Metab Date: 1998-02 Impact factor: 5.958
Authors: M Tonacchera; P Vitti; P Agretti; G Ceccarini; A Perri; R Cavaliere; B Mazzi; A G Naccarato; P Viacava; P Miccoli; A Pinchera; L Chiovato Journal: J Clin Endocrinol Metab Date: 1999-11 Impact factor: 5.958
Authors: M Tonacchera; P Agretti; L Chiovato; V Rosellini; G Ceccarini; A Perri; P Viacava; A G Naccarato; P Miccoli; A Pinchera; P Vitti Journal: J Clin Endocrinol Metab Date: 2000-06 Impact factor: 5.958
Authors: M Tonacchera; P Agretti; V Rosellini; G Ceccarini; A Perri; M Zampolli; R Longhi; D Larizza; A Pinchera; P Vitti; L Chiovato Journal: Thyroid Date: 2000-10 Impact factor: 6.568